Airway diseases
Clinical trials session
ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Asthma
Aims : to present important clinical trials in respiratory medicine; to summarise key findings and discuss with the audience experts conclusions, to bring clinical trial’s abstracts into the clinical context. This session is led by a chair and two expert discussants who will facilitate the discussions and summarise key messages.
Target audience :
General practitioner, Trainee, Clinical researcher, Adult pulmonologist/Clinician, Scientist (basic, translational)
10:45
Characteristics of prominent response to triple therapy in patients with asthma uncontrolled on ICS/LABA: A stratified analysis of the TRIMARAN and TRIGGER studies
D. Singh(Manchester, United Kingdom)
COI
1
10:55
Efficacy and safety of once-daily low-dose indacaterol/mometasone via Breezhaler® in symptomatic adult and adolescent patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings
P. D'Andrea(Gillette, United States)
COI
2
11:05
Late Breaking Abstract - Comparison of mesh and jet nebulizers with different interfaces in acute moderate to severe paediatric asthma
G. Moody(Dallas, United States)
COI
3
11:15
Ten-year follow-up of subjects who received bronchial thermoplasty (BT) in 3 randomized controlled studies (BT10+)
R. Chaudhuri(Glasgow, United Kingdom)
COI
4
11:25
Wrap-up by discussant and discussion
C. Porsbjerg(Copenhagen, Denmark)
COI
5
RCT
11:50
Dupilumab (DPL) Efficacy in Patients With Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) with/without Nonsteroidal Anti-inflammatory Drug-Exacerbated Respiratory Disease (NSAID-ERD): SINUS-24, SINUS-52 Trials
J. Maspero(Ciudad Autónoma Buenos Aires, Argentina)
COI
6
12:00
Late Breaking Abstract - Effect of timapiprant, a DP2 antagonist, on airway inflammation in severe eosinophilic asthma
R. Dr Rahul Shrimanker(Bristol, United Kingdom)
COI
7
12:10
Tezepelumab decreases matrix remodelling and inflammatory pathways in patients with asthma
S. Sridhar(Gaithersburg, United States)
COI
8
12:20
Wrap-up by discussant and discussion
M. Gaga(Athens, Greece)
COI
9
RCT
. . .
